Showing 2261-2270 of 5771 results for "".
- Atia Vision Announces Upcoming Presentations Highlighting Modular Presbyopia-Correcting IOL Technologyhttps://modernod.com/news/atia-vision-announces-upcoming-presentations-highlighting-modular-presbyopia-correcting-iol-technology/2476867/Atia Vision announced its technology will be featured in presentations at two ophthalmology conferences this week in Paris, France. The first presentation will be delivered by the company during the Ophthalmology Futures European Forum, a clinician-driven global m
- EyePoint Pharmaceuticals Announces Data Highlighting Yutiq to be Presented at Retina Society Scientific Meetinghttps://modernod.com/news/eyepoint-pharmaceuticals-announces-data-highlighting-yutiq-to-be-presented-at-retina-society-scientific-meeting/2476859/EyePoint Pharmaceuticals announced that two abstracts supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for chronic, noninfectious uveitis affecting the posterior segment of the eye have been accepted for two oral presentations at the 5
- Allergan and Molecular Partners Announce Acceptance of FDA BLA for Abicipar Pegol in Patients With Wet AMDhttps://modernod.com/news/allergan-and-molecular-partners-announce-acceptance-of-fda-biologics-license-application-for-abicipar-pegol-in-patients-with-wet-amd/2479537/Allergan and Molecular Partners announced that the FDA has accepted a biologics license application (BLA) and the European Medicines Agency (EMA) has validated a marketing authorization application (MAA) for Abicipar pegol, a novel, investigational DARPin therapy in patients with wet age-related
- Staar Surgical Announces EVO ICL Clinical Program for Its 16th Annual Surgical Experts Summit in Parishttps://modernod.com/news/staar-surgical-announces-evo-icl-clinical-program-for-its-16th-annual-surgical-experts-summit-in-paris/2479541/Staar Surgical announced the EVO ICL Clinical Program, which will be presented by ophthalmic surgeons to ophthalmic surgeons at its invitation only Surgical Experts Summit, is expected to be attended by over 250 surgeons and invited clinician guests from 46 countries. The Experts Summit will be h
- Novartis Announces EU Approval of Lucentis for Preterm Infants With Retinopathy of Prematurity (ROP)https://modernod.com/news/novartis-announces-eu-approval-of-lucentis-for-preterm-infants-with-retinopathy-of-prematurity-rop/2476856/Novartis announced the European approval of Lucentis (ranibizumab) for preterm infants with retinopathy of prematurity (ROP), making it the first and only licensed pharmacological treatment for this indication. The approval is based on the landmark RAINBOW study, showing Lucentis is an eff
- iSTAR Medical Announces EUR 40 Million Series C Financinghttps://modernod.com/news/istar-medical-announces-eur-40-million-series-c-financing/2479542/iSTAR Medical announced the completion of a €40m Series C financing to support the development of iSTAR Medical’s MINIject device along the path to commercialization in Europe and the United States. MINIject, an ab-interno MIGS device, provides a powerful and reliable sol
- Staar Surgical Announces Strategic Alliance Agreement with Asian Eye Institutehttps://modernod.com/news/staar-surgical-announces-strategic-alliance-agreement-with-asian-eye-institute/2476850/Staar Surgical Company announced that it has entered a strategic alliance with Asian Eye Institute, an eye care group with nine locations in the Philippines. Asian Eye Institute was founded in 2001 and has 18 medical doctors, two specialist optometrists, and more than 30 staff optometrists on sta
- Regenxbio Announces License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314https://modernod.com/news/regenxbio-announces-exclusive-worldwide-license-agreement-with-clearside-biomedical-for-evaluation-of-in-office-delivery-platform-for-rgx-314/2476851/Regenxbio and Clearside Biomedical announced an option and license agreement for exclusive worldwide rights to Clearside’s proprietary, in-office SCS Microinjector for the delivery of RGX-314 to the suprachoroidal space to treat wet age-related macular degeneration (AMD), diabetic
- Santen Announces Topline Data for DE-128 (MicroShunt) Demonstrating Reductions in IOP and Medication Use in Patients With Glaucomahttps://modernod.com/news/santen-announces-topline-data-for-de-128-microshunt-demonstrating-reductions-in-iop-and-medication-use-in-patients-with-glaucoma/2476840/Santen Pharmaceutical announced the results of INN-005, a prospective, randomized, controlled, single-masked, multicenter study to assess the safety and effectiveness of DE-128 (MicroShunt) standalone, without concomitant cataract extraction. The study compared DE-128 implanted intraoperatively w
- Topcon Announces the Release of Harmony Into the EMEA Regionhttps://modernod.com/news/topcon-announces-the-release-of-harmony-into-the-emea-region/2476835/Topcon has announced the release and clearance of the Topcon Harmony, a class II medical diagnostic software, into the EMEA market. Topcon Harmony is a responsive browser-based software application for on-site or cloud-hosted environments that allows practitioners to connect all of their diagnost